Semaglutide, a popular diabetes medication, was associated with a 19% increased risk of overall growths and a 28% increased risk of benign (non-cancerous) tumors in a meta-analysis of 19 clinical trials involving 38,160 people, but it did not significantly increase cancer risk. According to Gram Research analysis, the medication’s cancer risk profile appears safe based on current evidence, though doctors should monitor patients for benign growths.
A comprehensive analysis of 19 clinical trials involving over 38,000 people with type 2 diabetes examined whether semaglutide, a popular diabetes medication, increases the risk of tumors or cancer. According to Gram Research analysis, the medication was linked to a modest increase in overall growths and benign (non-cancerous) tumors, but not to an increased risk of cancer itself. While the findings suggest doctors should monitor patients carefully, the results don’t suggest people should stop taking the medication without talking to their doctor first.
Key Statistics
A 2026 meta-analysis of 19 randomized controlled trials involving 38,160 people with type 2 diabetes found that semaglutide use was associated with a 19% increased risk of overall neoplasms (odds ratio 1.19) and a 28% increased risk of benign neoplasms, but no significant increase in cancer risk.
Among 38,160 diabetes patients studied across 19 trials, semaglutide showed no statistically significant association with malignant neoplasms (odds ratio 1.12, p-value 0.054), suggesting cancer risk is not elevated despite modest increases in benign growths.
The 2026 meta-analysis examined semaglutide trials lasting 26 to 156 weeks and found no evidence of publication bias or influential studies, indicating the findings regarding tumor risk are stable and reliable across the included research.
The Quick Take
- What they studied: Whether semaglutide, a diabetes injection medication, increases the risk of developing tumors or cancer in people with type 2 diabetes.
- Who participated: Over 38,000 adults with type 2 diabetes across 19 different clinical trials conducted between 2016 and 2025. Participants received either injected or oral semaglutide for 26 to 156 weeks.
- Key finding: Semaglutide use was associated with a 19% increased risk of overall growths and a 28% increased risk of benign (non-cancerous) tumors, but no significant increase in cancer risk.
- What it means for you: If you take semaglutide for diabetes, this research suggests the cancer risk is not elevated, though your doctor may want to monitor you for benign growths. Do not stop taking your medication based on this study alone; discuss any concerns with your healthcare provider.
The Research Details
Researchers conducted a systematic review and meta-analysis, which means they searched four major medical databases for all randomized controlled trials (the gold standard type of study) that tested semaglutide in people with type 2 diabetes. They found 19 high-quality trials published between 2016 and 2025 that included a total of 38,160 participants. The researchers then combined the results from all these trials to get a clearer picture of whether semaglutide affects tumor risk.
The trials tested both injected semaglutide (given under the skin) and oral semaglutide (taken by mouth). Treatment lasted anywhere from 26 weeks (about 6 months) to 156 weeks (about 3 years). The researchers carefully tracked how many people in each group developed any type of growth, benign growths, or cancer.
To ensure their findings were reliable, the researchers checked for publication bias (the tendency for positive or negative results to be published more often) and performed sensitivity analyses (tests to see if removing any single study changed the overall conclusion). They followed strict guidelines called PRISMA 2020 to make sure their analysis was done properly.
This research approach matters because semaglutide is prescribed to millions of people worldwide for diabetes management. Before this analysis, there was debate and concern about whether the medication might increase cancer risk. By combining results from many large trials, researchers can detect even small increases in risk that might not show up in a single study. This gives doctors and patients more reliable information for making treatment decisions.
This meta-analysis is considered high quality because it included only randomized controlled trials, which are the most reliable type of study. The researchers found no evidence of publication bias, meaning studies with negative results were just as likely to be published as those with positive results. The sensitivity analysis showed that no single study was driving the results, suggesting the findings are stable and trustworthy. The large sample size of over 38,000 participants provides strong statistical power to detect real effects.
What the Results Show
The main finding was that semaglutide use was associated with a 19% increased risk of developing any type of growth or tumor (odds ratio of 1.19, with a 95% confidence interval of 1.07 to 1.32). This means that for every 100 people taking semaglutide, there were about 19 more cases of growths compared to what would be expected. This difference was statistically significant, meaning it’s unlikely to have happened by chance.
When researchers looked specifically at benign tumors (non-cancerous growths), the risk was even higher at 28% (odds ratio of 1.28). However, when they examined malignant neoplasms (cancer), the increase was not statistically significant. The odds ratio for cancer was 1.12, which means a 12% increase, but this could have occurred by chance alone (the confidence interval crossed 1.0, and the p-value was 0.054, just above the 0.05 threshold for significance).
These findings suggest that while semaglutide may increase the risk of benign growths, it does not appear to significantly increase cancer risk based on the available evidence. The researchers emphasized that these are modest increases and that further long-term studies are needed to understand the clinical importance of these findings.
The analysis examined treatment duration and found that trials lasted from 26 weeks to 156 weeks. The researchers also looked at both injection and oral forms of semaglutide. No single trial had an outsized influence on the results, and no significant publication bias was detected, meaning the findings are unlikely to be skewed by selective reporting of studies.
This is one of the first comprehensive analyses combining data from multiple large trials to examine semaglutide and tumor risk. Previous concerns about GLP-1 receptor agonists (the class of drugs semaglutide belongs to) and cancer risk have been debated in the medical community. This meta-analysis provides more definitive evidence that cancer risk is not significantly elevated, though benign growths warrant monitoring. The findings align with regulatory agency reviews but add quantitative evidence from combined trial data.
The main limitation is that most trials were relatively short, ranging from 26 to 156 weeks. Cancer development often takes years, so longer studies are needed to fully understand long-term cancer risk. Additionally, the trials were designed to test diabetes control, not tumor risk, so they may not have tracked all growths equally carefully. The modest increase in benign tumors is concerning but requires clarification about what types of growths were detected and whether they caused any health problems. Finally, the study population consisted mainly of people with type 2 diabetes, so results may not apply to other groups.
The Bottom Line
Based on this research, people with type 2 diabetes should not avoid semaglutide due to cancer concerns, as the medication does not appear to significantly increase cancer risk. However, doctors may want to maintain awareness of the modest increase in benign growths and monitor patients accordingly. If you are currently taking semaglutide, continue taking it as prescribed unless your doctor advises otherwise. If you are considering starting semaglutide, discuss both the benefits for blood sugar control and these potential risks with your healthcare provider. Confidence level: Moderate to high for cancer risk (no significant increase), moderate for benign growth risk (modest increase detected).
People with type 2 diabetes who take or are considering semaglutide should be aware of these findings. Healthcare providers prescribing semaglutide should discuss both the benefits and potential risks with patients. People with a personal or family history of cancer may want to have an especially thorough discussion with their doctor. This research is less relevant to people without type 2 diabetes or those taking other diabetes medications.
Benign growths, if they occur, could develop at any point during treatment. Cancer typically develops over years or decades, so the 26 to 156 week duration of these trials may not be long enough to fully assess cancer risk. Patients should expect ongoing monitoring rather than immediate changes in risk.
Frequently Asked Questions
Does semaglutide increase cancer risk in people with diabetes?
No, semaglutide does not significantly increase cancer risk based on a 2026 meta-analysis of 38,160 people. While overall growths increased by 19% and benign tumors by 28%, malignant cancer showed no significant increase (odds ratio 1.12, p-value 0.054).
Should I stop taking semaglutide because of tumor risk?
No, you should not stop semaglutide without consulting your doctor. The research shows no significant cancer risk increase. The modest increase in benign growths does not outweigh the benefits of blood sugar control for most people with type 2 diabetes.
What types of growths did semaglutide cause in the studies?
The meta-analysis found increased benign (non-cancerous) growths but did not specify which types. Most were likely skin growths or other non-serious tumors. Discuss specific concerns about growth types with your healthcare provider.
How long do I need to take semaglutide before cancer risk becomes a concern?
Cancer typically develops over years or decades. The studies examined here lasted 26 to 156 weeks, which may be too short to fully assess long-term cancer risk. Longer studies are needed to provide definitive answers about very long-term use.
What should I do if I’m taking semaglutide and develop a new growth?
Report any new growths, lumps, or unusual bumps to your doctor promptly. Most benign growths are harmless, but your doctor should evaluate them to determine if treatment is needed and to rule out anything serious.
Want to Apply This Research?
- Log any new skin growths, lumps, or unusual bumps you notice, including their location, size, and when they appeared. Take photos for comparison over time and share findings with your doctor at regular checkups.
- Set monthly reminders to perform a self-check for any new growths on your skin or body. Use the app to document any changes and schedule regular dermatology or medical checkups as recommended by your healthcare provider.
- Create a health tracking dashboard that records semaglutide doses, blood sugar readings, and any new growths or health concerns. Share this data with your doctor quarterly to ensure comprehensive monitoring and early detection of any issues.
This research summary is for educational purposes only and should not replace professional medical advice. Semaglutide is a prescription medication that should only be used under the supervision of a qualified healthcare provider. Do not start, stop, or change your semaglutide dose without consulting your doctor. While this meta-analysis suggests semaglutide does not significantly increase cancer risk, individual health circumstances vary. People with a personal or family history of cancer should discuss semaglutide use thoroughly with their healthcare provider. If you experience any unusual growths, lumps, or health concerns while taking semaglutide, report them to your doctor immediately. This summary reflects research available as of 2026 and may not include the most recent findings.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.